Autologous hematopoietic stem cell transplantation(auto-HSCT)is an effective way to treat various malignant hematopoietic diseases and solid tumors,among which stem cell mobilization is the key step.Traditional mobilization agents,such as granulocyte colony-stimulating factor(G-CSF)with or without chemotherapy,often cause a failure in mobilization.New mobilization agents,such as plerixafor and motixafortide,which block the interaction of C-X-C chemokine receptor type 4(CXCR4)/stromal cell derived factor(SDF-1)between hematopoietic stem cells and stromal cells,have been approved for clinical utilization.Meanwhile some mobilization agents in preclinical stage,such as burixafor and HF51116,display encouraging effects.Plerixafor,no matter whether it is combined with G-CSF or with G-CSF plus chemotherapy,mobilizes more CD34+cell from bone marrow to peripheral blood than control.Higher ratio of effect to cost is found when plerixafor is used in condition of"on-demand","just-in-time","in-advance".Motesafotide has higher CXCR4 binding affinity and longer clinical activity time than plerixafor does.Although the new mobilization agent has shown a certain degree of superiority,further research is needed on cost,safety,and optimal application strategies.Mobilization agents targeting the interaction between hematopoietic stem cells and stromal cells,such as P-selectin,VLA-4(a4β1,and CXCR2 inhibitors,are still in research.
维普
万方数据